Health: Scientists have developed an effective remedy for kidney cancer – CPV.ru

 
 

Immediately two new drugs that could radically change the treatment of patients with kidney cancer at later stages, were presented to the European Cancer Congress (ECC).

Recall now kidney cancer – this is one of the most common cancers which at a later stage characterized by a high mortality rate of patients. Today, nine out of ten people suffering from this disease die within five years after the metastases begin to spread to other parts of the body.

However, new medicines «Nivolumab» and «Cabozantinib», the first of which activates the immune system, and the second suppresses signals at the uncontrolled division of cells in the tumor is likely to become the first effective step to combat the effects of kidney cancer in the later stages.

The drug «Nivolumab» was developed as a monoclonal antibody which prevents cancer cells off the human immune system by reducing the proliferation (growth of cancer cells) and T-cell activation. This type of medicines has already positively proved itself in the treatment of cancer of the skin and lungs. Do not disappoint «Nivolumab» and in the course of a clinical trial, when he managed to extend the life of 821 hopeless patients who were in the later stages of kidney cancer, from 19.6 to 25 months. This time, according to Dr. James Larkin from the Royal Marsden Hospital, must be physicians, to expand the arsenal available today means to fight against this deadly cancer disease.

Moreover, the medicine, according to Dr. Larkin, a real breakthrough to use immunotherapy against cancer, which proves the effectiveness of analogs of this drug, work on which is actively past two years, in the fight against other forms of cancer.

has proved its effectiveness in the fight against kidney cancer in the later stages, and drug «Cabozantinib», which in clinical trials has extended the life of hopeless patients from 3.8 to 7.4 months by suppressing signals, causing uncontrolled cell division in cancer.

According to the conference participants, the creation of these drugs which is much more effective and have fewer side effects than their predecessors, provide an opportunity for a new, simultaneously acting on the immune system and cancer, approach to the treatment of kidney cancer at a late stage, which was previously considered hopeless in terms of the recovery of patients.